Back to top
more

Unum Therapeutics Inc. (UMRX)

(Delayed Data from NSDQ)

$3.35 USD

3.35
22,165

+0.07 (2.13%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?

Is (UMRX) Outperforming Other Medical Stocks This Year?

Is Unum Therapeutics (UMRX) Stock Outpacing Its Medical Peers This Year?

Is (UMRX) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics

The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics

Sweta Killa headshot

Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside

On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q2 revenues increase year over year.

Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Is Unum Therapeutics (UMRX) Outperforming Other Medical Stocks This Year?

Is (UMRX) Outperforming Other Medical Stocks This Year?

Unum Therapeutics Inc. (UMRX) Outpaces Stock Market Gains: What You Should Know

Unum Therapeutics Inc. (UMRX) closed the most recent trading day at $2.74, moving +1.86% from the previous trading session.

Dynavax Signs a Pact to Develop Universal Influenza Vaccine

Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.

Top Ranked Momentum Stocks to Buy for July 17th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 17th

Nabriva Soars on Agreement With Merck to Distribute Sivextro

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020

Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.

Axsome's NDA for Depressive Disorder Drug on Track in Q420

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.

Top Ranked Momentum Stocks to Buy for July 10th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 10th

Unum Therapeutics Inc. (UMRX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).

Unum Therapeutics (UMRX) Catches Eye: Stock Jumps 8.6%

Unum Therapeutics (UMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Unum Therapeutics Inc (UMRX) Reports Q1 Loss, Tops Revenue Estimates

Unum Therapeutics Inc (UMRX) delivered earnings and revenue surprises of 39.39% and 134.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?

During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.

Unum Therapeutics Inc. (UMRX) Q4 Earnings and Revenues Beat Estimates

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of 120.00% and 271.07%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Unum Therapeutics Inc. (UMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Unum Therapeutics Inc. (UMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Unum Therapeutics Inc. (UMRX) Reports Q3 Loss, Misses Revenue Estimates

Unum Therapeutics Inc. (UMRX) delivered earnings and revenue surprises of -25.81% and -76.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?